| Oct 4 |
Myriad and Ultima to study UG 100 sequencing platform for genomics clinical tests
|
| Oct 3 |
Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics
|
| Oct 1 |
Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
|
| Oct 1 |
BMRN or MYGN: Which Is the Better Value Stock Right Now?
|
| Sep 19 |
Myriad Genetics a new equal-weight at Morgan Stanley: sustained growth eyed
|
| Sep 19 |
Myriad Genetics Has Many Opportunities for Growth, Needs Sustained Execution, Morgan Stanley Says
|
| Sep 18 |
Here's Why Myriad Genetics (MYGN) is a Strong Momentum Stock
|
| Sep 18 |
Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference
|
| Sep 17 |
Should You Continue to Retain MYGN Stock in Your Portfolio?
|
| Sep 13 |
Insider Sale: Chief Scientific Officer Dale Muzzey Sells Shares of Myriad Genetics Inc (MYGN)
|
